查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2011182

放射性藥物市場：2026-2032年全球市場預測（按放射性同位素類型、製造技術、應用和最終用戶分類）

Radiopharmaceuticals Market by Radioisotope Type, Production Technology, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，放射性藥物市場價值將達到 58.4 億美元，到 2026 年將成長到 62 億美元，到 2032 年將達到 91.9 億美元，複合年成長率為 6.69%。

主要市場統計數據
基準年 2025 58.4億美元
預計年份：2026年 62億美元
預測年份 2032 91.9億美元
複合年成長率 (%) 6.69%

對當今放射性藥物市場格局進行簡要概述，重點關注技術、臨床需求以及影響產業決策的策略重點。

全球放射性藥物產業正經歷技術快速發展和策略重組的時期。同位素生產和自動化的最新創新降低了臨床和研究領域眾多終端使用者的操作複雜性，同時，多個治療領域日益成長的臨床需求也使得供應鏈韌性和合規性備受關注。隨著相關人員重新評估籌資策略和資金配置，亟需進行簡潔、以證據為基礎且全面性的分析，將技術、臨床應用和終端使用者能力整合到一個切實可行的決策架構中。

同位素生產的去中心化、治療診斷學的進步以及監管政策的澄清，正在如何重塑放射性藥物的臨床應用和商業性機會？

放射性藥物領域正經歷一場變革，其驅動力來自治療診斷學生產技術的創新、診療一體化技術的進步以及靶向臨床應用證據基礎的不斷擴大。迴旋加速器效率的提升和小型化發生器系統的改進，使得關鍵同位素的取得更加分散化，讓地方醫院和診斷中心能夠探索先前只有大規模學術機構才能實現的現場或近場生產模式。同時，先進合成模組帶來的自動化正在減少人工操作時間，提高生產過程的可重複性，即使在更嚴格的監管要求下也能實現高通量生產。

美國2025年關稅的最新進展促使放射性藥物相關人員重組其供應鏈、將生產轉移到近岸地區，並改變其庫存策略。

美國將於2025年實施關稅及貿易政策調整，將進一步加劇依賴跨國供應鏈取得放射性前驅物、設備和成品放射性藥物的利害關係人的困境。進口關稅和合規程序增加了從海外供應商採購專用組件的成本和行政負擔，迫使許多機構重新評估其供應商基礎和物流策略。為此，多家製造商和臨床網路正在加速推動近岸外包和垂直整合，以降低關稅變化帶來的風險，並確保關鍵同位素和耗材供應鏈的持續性。

將同位素特性、生產方法、臨床應用和最終用戶操作實踐與策略性投資選擇聯繫起來的實用、細分主導的見解。

細分市場層面的洞察揭示了特定細分市場的趨勢，這些趨勢應指南產品開發、商業化和營運投資。根據放射性同位素的類型，氟-18、鎵-68、碘-131、鎦-177 和Technetium-99m 各有不同的臨床和物流特性，因此在生產計劃、低溫運輸管理和監管文件方面需要考慮不同的因素。換句話說，製造商必須調整其產能和品管系統，以適應每種同位素的崩壞特性和處理限制。根據製造技術，製造方法的選擇——自動化合成模組、迴旋加速器、產生器和核子反應爐——需要在資本密集度、處理能力和地理柔軟性之間進行權衡。這些權衡應體現在網路設計和資本分配決策中。

美洲、歐洲、中東和非洲以及亞太地區的區域基礎設施、監管多樣性和臨床重點如何決定准入模式和戰略夥伴關係。

區域趨勢影響供應方的策略選擇和臨床實施路徑。在美洲，對先進迴旋加速器基礎設施的投資以及緊密的醫院和診斷中心網路，為擴大短壽命同位素的生產和試點分散式模式創造了有利環境，使用於影像和治療的放射性核素更貼近患者。另一方面，區域監管協調和報銷方案的差異要求採取個人化的市場准入策略，並且需要與當地保險公司密切合作才能確保成功實施。

塑造該行業的競爭策略包括垂直整合、與醫療診斷治療診斷學合作、投資自動化以及擴大契約製造。

產業領導者正透過垂直整合、策略夥伴關係以及對自動化和品管系統的重點投資來實現差異化競爭。一些企業正在投資建造模組化和擴充性的生產設施，以支援分散式供應鏈模式；而其他企業則尋求與製藥研發公司合作，共同開發治療診斷學化合物和伴隨診斷試劑。同時，合約研發生產（CDMO）服務商也在拓展服務範圍，將灌裝包裝、放射性標記和供應鏈管理服務納入其中，以應對小規模生物技術創新者和成熟製造商所面臨的特定挑戰。

為放射性藥物領域的產業領導者提供切實可行的、重點突出的策略措施，以加強供應鏈、加速臨床部署並確保競爭優勢。

產業領導者應優先採取一系列切實可行且影響深遠的措施，以增強韌性和商業性潛力。首先，他們應加快對生產基地的評估，重點關注模組化、擴充性的資產，以支援短半衰期同位素的分散式供應，並在能夠降低變異性和勞動密集度的領域整合自動化。其次，他們應尋求選擇性的近岸外包和區域夥伴關係，以降低關稅風險並縮短物流路線，同時與多家供應商簽訂關鍵前體和耗材的契約，以降低單一來源風險。

我們透過透明且可重複的研究過程，結合專家訪談、技術檢驗和文獻整合，為放射性藥物提供實用見解。

本執行摘要依據的研究整合了一級資訊來源和二級資訊來源，在保持方法論透明度的同時，提供了基於證據的觀點。一級資訊來源包括對生產經理、臨床經理和供應鏈經理的結構化訪談，以及與迴旋加速器運作、產生器技術和自動化合成領域專家的技術諮詢。二級資訊來源包括監管指南、同儕審查的臨床文獻以及生產設施的營運數據，這些數據用於評估產量、品質系統和物流實踐。

結論強調韌性、實證採納和策略能力建構是放射性藥物領域未來成功的決定因素。

總之，放射性藥物產業正朝著更分散化、實證化和以品質為中心的模式發展。生產技術和自動化的進步推動了製造地的多元化，而治療診斷學的發展則為臨床和商業性合作開闢了新的途徑。同時，政策變革和貿易措施促使人們重新評估供應鏈設計和籌資策略，凸顯了韌性和營運柔軟性的重要性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：放射性同位素放射性藥物市場

  • 氟-18
  • 鎵-68
  • 碘-131
  • 鎦-177
  • Technetium-99m

第9章：依生產技術分類的放射性藥物市場

  • 自動合成模組
  • 迴旋加速器系統
  • 生成器方法
  • 核子反應爐基地

第10章：放射性藥物市場：依應用領域分類

  • 循環系統
  • 內分泌學
  • 神經病學
  • 腫瘤學

第11章：放射性藥物市場：依最終用戶分類

  • 診所
  • 診斷中心
  • 醫院
  • 研究機構

第12章：放射性藥物市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：放射性藥物市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：放射性藥物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國放射性藥物市場

第16章：中國放射性藥物市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Advanced Accelerator Applications
  • Bayer AG
  • Bracco Imaging SpA
  • Cardinal Health Inc.
  • Curium Pharma
  • Eli Lilly and Company
  • Fusion Pharmaceuticals Inc.
  • GE Healthcare
  • IBA Molecular
  • ImaginAb Inc.
  • Jubilant Pharma Limited
  • Lantheus Holdings Inc.
  • Norgine BV
  • NorthStar Medical Radioisotopes LLC
  • Novartis AG
  • NuView Life Sciences
  • Pharmalogic LLC
  • Positron Corporation
  • RadioMedix Inc.
  • Telix Pharmaceuticals Limited
  • Theragnix Technologies LLC
  • Zevacor Pharma Inc.
Product Code: MRR-4308E1C887A3

The Radiopharmaceuticals Market was valued at USD 5.84 billion in 2025 and is projected to grow to USD 6.20 billion in 2026, with a CAGR of 6.69%, reaching USD 9.19 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.84 billion
Estimated Year [2026] USD 6.20 billion
Forecast Year [2032] USD 9.19 billion
CAGR (%) 6.69%

A succinct orientation to today's radiopharmaceutical environment highlighting technology, clinical demand, and strategic priorities shaping industry decisions

The global radiopharmaceutical landscape is undergoing a period of accelerated technological evolution and strategic repositioning. Recent innovations in isotope production and automation have reduced complexity for many clinical and research end users, while rising clinical demand across multiple therapeutic areas has intensified attention on supply chain resilience and regulatory alignment. As industry stakeholders reassess procurement strategies and capital allocation, they require concise, evidence-based synthesis that links technology, clinical application, and end-user capacity to practical decision frameworks.

This executive summary synthesizes complex developments into actionable insight, emphasizing how production modalities, isotope diversity, and application-specific dynamics converge to shape operational priorities. It frames the major trends influencing investment, partnerships, and commercialization, while clarifying implications for manufacturers, clinical service providers, and policy makers. By focusing on structural drivers rather than speculative projections, the introduction grounds subsequent analysis in observable shifts in technology adoption, regulatory posture, and clinical demand patterns. Consequently, readers will gain a clear starting point for evaluating where to focus strategic effort in the near and medium term.

How decentralization of isotope production, theranostics momentum, and regulatory clarity are reshaping clinical access and commercial opportunity for radiopharmaceuticals

The radiopharmaceutical sector is experiencing transformative shifts driven by innovation in radioisotope production, advances in theranostics, and an expanding evidence base for targeted clinical applications. Developments in cyclotron efficiency and compact generator systems are decentralizing access to key isotopes, enabling community hospitals and diagnostic centers to contemplate onsite or near-site production models where previously only large academic centers could participate. At the same time, automation through advanced synthesis modules is reducing hands-on time, improving reproducibility, and enabling higher throughput under tighter regulatory requirements.

Theranostic approaches have elevated the commercial and clinical value of certain radionuclides, prompting strategic partnerships between molecular imaging companies, pharmaceutical developers, and contract manufacturers. This convergence is further supported by expanding clinical trials in oncology and neurology, which are generating robust datasets that inform reimbursement discussions and clinical adoption. Additionally, regulatory authorities are increasingly issuing guidance that clarifies manufacturing quality expectations for novel radioligands, thereby lowering barriers to scale when sponsors can meet these standards. Overall, the landscape is moving toward a more distributed yet quality-focused ecosystem, where agility, manufacturing reliability, and clinical evidence become decisive competitive differentiators.

How recent United States tariff developments in 2025 are prompting supply chain reconfiguration, nearshoring, and inventory strategy changes across radiopharmaceutical stakeholders

The introduction of tariffs and trade policy shifts in the United States in 2025 has introduced an additional layer of complexity for stakeholders that depend on cross-border supply chains for precursors, equipment, and finished radiopharmaceuticals. Import duties and compliance processes have increased the cost and administrative burden associated with sourcing specialized components from international suppliers, which has prompted many organizations to reevaluate their supplier base and logistics strategies. In response, several manufacturers and clinical networks have accelerated nearshoring and vertical integration efforts to reduce exposure to tariff volatility and to secure continuity of supply for critical isotopes and consumables.

Meanwhile, transitional frictions in customs clearance and increased scrutiny of product classification have lengthened lead times for certain imported goods, encouraging greater inventory buffers and contractual contingencies. As a result, procurement teams are placing greater emphasis on validated domestic supply options, multi-sourcing strategies, and the development of in-region manufacturing capabilities. These adjustments, in turn, influence capital planning, site selection for production assets, and decisions regarding strategic stockpiles. In sum, the tariff environment has catalyzed a rethink of supply chain robustness, compelling organizations to balance cost pressures with the imperative of uninterrupted clinical delivery.

Actionable segmentation-driven insights linking isotope characteristics, production modalities, clinical applications, and end-user operating realities to strategic investment choices

Segment-level intelligence reveals differentiated dynamics that should guide product development, commercialization, and operational investments. Based on Radioisotope Type, the clinical and logistical profiles of Fluorine-18, Gallium-68, Iodine-131, Lutetium-177, and Technetium-99m each present distinct considerations for production scheduling, cold chain management, and regulatory documentation, which means manufacturers must align capacity and quality systems to the decay characteristics andhandling constraints of each isotope. Based on Production Technology, choices between Automated Synthesis Modules, Cyclotron Based, Generator Based, and Reactor Based production create trade-offs between capital intensity, throughput, and geographic flexibility, and these trade-offs should inform network design and capital allocation decisions.

Based on Application, the clinical pathways and reimbursement trajectories vary significantly across Cardiology, Endocrinology, Neurology, and Oncology, so commercial teams must tailor evidence generation and payer engagement strategies to the clinical value propositions relevant to each specialty. Based on End User, operational and service models differ between Clinics, Diagnostic Centres, Hospitals, and Research Institutes, affecting demand patterns, procurement lead times, and the types of service agreements that will be most compelling. Taken together, these segmentation lenses enable organizations to prioritize investments in production technology and clinical evidence according to the intersection of isotope attributes, manufacturing capabilities, therapeutic use cases, and end-user operating realities. Consequently, segmentation-driven strategies will be central to achieving operational efficiency and commercial traction.

How regional infrastructure, regulatory diversity, and clinical priorities across the Americas, Europe, Middle East & Africa, and Asia-Pacific determine access models and strategic partnerships

Regional dynamics shape both supply-side strategic choices and the pathways for clinical adoption. In the Americas, investment in advanced cyclotron infrastructure and a dense network of hospitals and diagnostic centers create a favorable environment for scaling production of short-lived isotopes and for piloting decentralized models that bring imaging and therapeutic radionuclides closer to patients. Conversely, regulatory harmonization and reimbursement variability across jurisdictions require tailored market-entry approaches and close engagement with regional payers to secure adoption.

In Europe, Middle East & Africa, diverse regulatory regimes and variable access to capital mean that partnerships and contract manufacturing arrangements are often the most efficient route to expand clinical availability, while regional hubs with reactor or cyclotron capacity continue to supply neighboring markets. Many countries in this region are actively investing in capability building, which opens opportunities for technology transfer and training programs. In the Asia-Pacific region, rapid expansion of clinical imaging infrastructure and strong government support for biotechnology have accelerated local production capabilities and interest in theranostic agents, yet fragmented regulatory pathways and differing clinical practice patterns require nuanced market access strategies. Across regions, cross-border collaboration, supply chain redundancy, and targeted clinical evidence programs remain essential to manage operational risk and to accelerate patient access.

Competitive strategies shaping the sector including vertical integration, partnerships for theranostics, automation investments, and contract manufacturing expansion

Leading industry participants are differentiating themselves through a combination of vertical integration, strategic partnerships, and focused investments in automation and quality systems. Some organizations are investing in modular, scalable production assets to support decentralized delivery models, while others pursue collaborations with pharmaceutical developers to co-develop theranostic compounds and companion diagnostics. In parallel, contract development and manufacturing providers are expanding service portfolios to include fill-finish, radiolabeling, and supply chain management services that address specific pain points for both small biotech innovators and established manufacturers.

Strategic M&A and licensing arrangements are also reshaping competitive positioning, enabling faster access to new isotopes, intellectual property, and distribution networks without the lead time associated with greenfield production. Equally important, companies that invest early in automation of synthesis modules and in robust quality-by-design approaches are achieving greater reproducibility and regulatory readiness, which can shorten time-to-market for novel radioligands. Finally, alliances with clinical networks and academic centers support evidence generation while providing pathways for real-world performance data that inform reimbursement and guideline inclusion decisions. Collectively, these company-level tactics illustrate how operational capability, strategic partnerships, and evidence generation are being used to build defensible market positions.

A focused set of practical strategic moves for industry leaders to fortify supply chains, accelerate clinical adoption, and secure competitive advantage in radiopharmaceuticals

Industry leaders should prioritize a set of practical, high-impact actions to strengthen resilience and commercial potential. First, accelerate evaluation of production footprints with an emphasis on modular, scalable assets that support decentralized delivery for short-lived isotopes, integrating automation where it reduces variability and labor intensity. Second, pursue selective nearshoring or regional partnerships to mitigate tariff exposure and to shorten logistical pathways, while also establishing multi-sourcing agreements for critical precursors and consumables to reduce single-source risk.

Third, align clinical evidence generation with payer expectations by designing trials and real-world evidence programs that demonstrate clear clinical utility in Cardiology, Endocrinology, Neurology, and Oncology, investing in health economic models that translate clinical outcomes into value propositions for payers. Fourth, deepen collaborations with hospitals, diagnostic centres, clinics, and research institutes to pilot service models and to gather implementation data that improves uptake. Finally, strengthen regulatory and quality frameworks early in development to ensure readiness for diverse market requirements, and invest in workforce training to support operational resilience. Taken together, these actions will help organizations convert market insight into durable operational and commercial advantage.

Transparent and reproducible research processes combining expert interviews, technical validation, and literature synthesis to deliver actionable radiopharmaceutical insights

The research underpinning this executive summary synthesizes primary and secondary sources to deliver an evidence-based perspective while maintaining methodological transparency. Primary inputs include structured interviews with manufacturing leaders, clinical directors, and supply chain managers, as well as technical consultations with experts in cyclotron operations, generator technology, and automated synthesis. Secondary sources include regulatory guidance, peer-reviewed clinical literature, and operational data from production facilities that inform assessments of throughput, quality systems, and logistics practices.

Analytical methods employed qualitative triangulation to reconcile differing stakeholder perspectives and technical validation to ensure consistency with known decay and handling constraints for each isotope. Where appropriate, case examples were used to illustrate operational approaches without extrapolating into specific market sizing or forecasting. Throughout the research process, emphasis was placed on reproducibility and practical relevance, and findings were reviewed by independent subject-matter experts to ensure that conclusions reflect current technological capabilities, regulatory trends, and observable shifts in clinical adoption.

Concluding synthesis emphasizing resilience, evidence-driven adoption, and strategic capability building as the decisive factors for future success in radiopharmaceuticals

In conclusion, the radiopharmaceutical sector is evolving toward a more distributed, evidence-driven, and quality-centric model. Advances in production technologies and automation are enabling a diversification of manufacturing footprints, while the growth of theranostics is creating new pathways for clinical and commercial collaboration. At the same time, policy changes and trade measures are prompting a re-evaluation of supply chain design and procurement strategies, underscoring the importance of resilience and operational flexibility.

For decision-makers, the implications are clear: invest in adaptable production capabilities, prioritize emission of high-quality clinical evidence tailored to specific therapeutic areas, and cultivate regional partnerships that mitigate logistical and regulatory friction. By doing so, organizations can not only manage near-term disruptions but also position themselves to capture long-term clinical and commercial opportunities as the radiopharmaceutical ecosystem matures. These choices will materially influence the pace at which new diagnostics and therapeutics reach patients and will determine which organizations lead in an increasingly complex and competitive environment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Radiopharmaceuticals Market, by Radioisotope Type

  • 8.1. Fluorine-18
  • 8.2. Gallium-68
  • 8.3. Iodine-131
  • 8.4. Lutetium-177
  • 8.5. Technetium-99m

9. Radiopharmaceuticals Market, by Production Technology

  • 9.1. Automated Synthesis Modules
  • 9.2. Cyclotron Based
  • 9.3. Generator Based
  • 9.4. Reactor Based

10. Radiopharmaceuticals Market, by Application

  • 10.1. Cardiology
  • 10.2. Endocrinology
  • 10.3. Neurology
  • 10.4. Oncology

11. Radiopharmaceuticals Market, by End User

  • 11.1. Clinics
  • 11.2. Diagnostic Centres
  • 11.3. Hospitals
  • 11.4. Research Institutes

12. Radiopharmaceuticals Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Radiopharmaceuticals Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Radiopharmaceuticals Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Radiopharmaceuticals Market

16. China Radiopharmaceuticals Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Advanced Accelerator Applications
  • 17.6. Bayer AG
  • 17.7. Bracco Imaging S.p.A.
  • 17.8. Cardinal Health Inc.
  • 17.9. Curium Pharma
  • 17.10. Eli Lilly and Company
  • 17.11. Fusion Pharmaceuticals Inc.
  • 17.12. GE Healthcare
  • 17.13. IBA Molecular
  • 17.14. ImaginAb Inc.
  • 17.15. Jubilant Pharma Limited
  • 17.16. Lantheus Holdings Inc.
  • 17.17. Norgine BV
  • 17.18. NorthStar Medical Radioisotopes LLC
  • 17.19. Novartis AG
  • 17.20. NuView Life Sciences
  • 17.21. Pharmalogic LLC
  • 17.22. Positron Corporation
  • 17.23. RadioMedix Inc.
  • 17.24. Telix Pharmaceuticals Limited
  • 17.25. Theragnix Technologies LLC
  • 17.26. Zevacor Pharma Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL RADIOPHARMACEUTICALS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL RADIOPHARMACEUTICALS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA RADIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY FLUORINE-18, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY FLUORINE-18, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY FLUORINE-18, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY GALLIUM-68, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY GALLIUM-68, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY GALLIUM-68, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY IODINE-131, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY IODINE-131, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY IODINE-131, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY LUTETIUM-177, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY LUTETIUM-177, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY LUTETIUM-177, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY TECHNETIUM-99M, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY TECHNETIUM-99M, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY TECHNETIUM-99M, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY AUTOMATED SYNTHESIS MODULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY AUTOMATED SYNTHESIS MODULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY AUTOMATED SYNTHESIS MODULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY CYCLOTRON BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY CYCLOTRON BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY CYCLOTRON BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY GENERATOR BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY GENERATOR BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY GENERATOR BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY REACTOR BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY REACTOR BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY REACTOR BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY ENDOCRINOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY ENDOCRINOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC CENTRES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC CENTRES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC CENTRES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICALS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. MIDDLE EAST RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. MIDDLE EAST RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. MIDDLE EAST RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 86. MIDDLE EAST RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 87. MIDDLE EAST RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. AFRICA RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. AFRICA RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. AFRICA RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 91. AFRICA RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 92. AFRICA RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. ASEAN RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. ASEAN RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. ASEAN RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 102. ASEAN RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 103. ASEAN RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. GCC RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GCC RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. GCC RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 107. GCC RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 108. GCC RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPEAN UNION RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPEAN UNION RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPEAN UNION RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPEAN UNION RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPEAN UNION RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. BRICS RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. BRICS RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. BRICS RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 117. BRICS RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 118. BRICS RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. G7 RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. G7 RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. G7 RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 122. G7 RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 123. G7 RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. NATO RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. NATO RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. NATO RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 127. NATO RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 128. NATO RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 131. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 133. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 134. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. CHINA RADIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 136. CHINA RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. CHINA RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 138. CHINA RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 139. CHINA RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)